Latest news with #RPGLifeSciences
News18
26-07-2025
- Business
- News18
RPG Life Sciences Q1 PAT falls marginally to Rs 26.29 cr
Mumbai, Jul 26 (PTI) RPG Life Sciences has reported a marginal decline in profit after tax (PAT) for the June 2025 quarter at Rs 26.29 crore against Rs 26.76 crore a year ago, according to a regulatory filing. Its revenue from operations for the reporting quarter, however, increased 2 per cent to Rs 168.92 crore from Rs 165.42 crore in Q1 FY25, the RPG group firm said. 'In Q1, we have sustained our sales growth momentum, reflecting the strength of our strategic execution and operational excellence," RPG Life Sciences Managing Director Ashok Nair said. He said the company's domestic formulations business continues to deliver market-beating growth, propelled by a focused transformation agenda and a customer-centric approach. 'We remain firmly on track to accelerate both our International Formulations and API segments, with growth driven by rapid onboarding of new customers, strategic expansion into newer markets, and launch of newer molecules that broaden our therapeutic reach," Nair stated. 'We are actively exploring inorganic growth opportunities across both formulations and APIs to further accelerate our growth trajectory and create lasting value for all stakeholders," Nair added. PTI IAS BAL BAL Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Business Standard
26-07-2025
- Business
- Business Standard
RPG Life Sciences standalone net profit declines 1.76% in the June 2025 quarter
Sales rise 2.12% to Rs 168.92 crore Net profit of RPG Life Sciences declined 1.76% to Rs 26.29 crore in the quarter ended June 2025 as against Rs 26.76 crore during the previous quarter ended June 2024. Sales rose 2.12% to Rs 168.92 crore in the quarter ended June 2025 as against Rs 165.42 crore during the previous quarter ended June 2024. Particulars Quarter Ended Jun. 2025 Jun. 2024 % Var. Sales 168.92165.42 2 OPM % 21.0023.62 - PBDT 40.5741.29 -2 PBT 35.4336.00 -2 NP 26.2926.76 -2
Business Standard
29-04-2025
- Business
- Business Standard
RPG Life edges higher after Q4 PAT rises 64% YoY to nearly Rs 22 crore
RPG Life Sciences advanced 3.79% to Rs 2188.80 after the company reported 64.3% increase in net profit to Rs 21.75 crore in Q4 FY25 from Rs 13.24 crore in Q4 FY25. Net sales rose by 12.7% year-over-year (YoY) to Rs 143.09 crore during the period under review. Total operating expenditure aggregated to Rs 117.60 crore in the quarter ended 31 March 2025, up by 10.7% YoY. Recorded EBITDA margin expanded from 23.3% in Q4 FY25 to 26.4% in Q4 FY25. In the March 2025 quarter, the company has recorded a profit of Rs 126.23 crore, which has resulted from assignment of surplus vacant leasehold land along with built-up structures situated at MIDC, Navi Mumbai. During the quarter, a fire incident had occurred at the companys manufacturing unit located at Navi Mumbai. The company had recognized an initial loss of Rs 24.83 crore and a corresponding credit of the two tranches of interim payment from the insurance company of Rs 8.50 crore, resulting in net initial loss of Rs 16.33 crore. These two items have resulted in the company recording a net exceptional gain of Rs 109.90 crore in Q4 FY25. Accordingly, profit before tax in Q4 FY25 stood at Rs 134.90 crore, up by 660.4% from Rs 17.74 crore recorded in Q4 FY24. Tax outgo for the fourth quarter was Rs 17.48 crore, up 220.7% YoY. RPG Life has reported 34.9% rise in net profit to Rs 118.26 crore on a 12.3% increase in net sales to Rs 653.43 crore in FY25 as compared with FY24. Yugal Sikri, managing director, RPG Life Sciences, said: "Thanks to our well-crafted transformation agenda, diligently pursued over the past five years, our first growth engine, Domestic Formulations business, has continued to register profitable and healthy growth consistently higher than the market. Thanks to our five pillar strategy, we are building brands, portfolios and therapies; increasing sales force productivity and nurturing strategic business assets. We are quite on course in shaping our International Formulations and API businesses to emerge as second and third growth engines by way of modernisation of both our API and Formulations plants, setting up new R&D units, developing a strong product pipeline, by infusion of significant capex. The International Formulations business is registering healthy double-digit profitable growth, and the API business is also showing promising profitable growth. Our structural approach of cost optimisation has helped us explore newer avenues in our operations to achieve cost efficiencies, thereby helping us to maintain our uninterrupted Y-o-Y margin expansion trajectory. The company has built sizeable cash surplus of Rs 168 crore from operations as a result of continued remarkable business performance. Additional cash generated by assignment of surplus vacant leasehold land at our Navi Mumbai plant has further augmented the pool to Rs. 266 crore. We are actively pursuing inorganic opportunities to accelerate business growth. RPG Life Sciences, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company is a research-based pharmaceutical company, producing a wide range of quality, affordable medicines.
Mint
29-04-2025
- Business
- Mint
Multibagger small-cap stock RPG Life Sciences jumps 12% on 800% surge in Q4 PAT, healthy dividend. Details here
Shares of Harsh Goenka-backed small-cap pharmaceuticals company RPG Life Sciences surged 12% in trade on Tuesday, April 29, following a massive surge in its March 2025 quarter profit and announcement of a healthy dividend. The company, post-market trading hours on Monday, posted its March 2025 quarter earnings, wherein it reported a 786% jump in profit after tax (PAT) to ₹ 117.35 crore, compared with ₹ 13.24 crore posted in the same quarter last year. Even on a sequential basis, Q4 PAT was 236% higher than ₹ 34.93 crore posted in the December 2024 quarter. Meanwhile, the company's revenue from operations jumped 12.67% year-on-year (YoY) to ₹ 143.09 crore in Q4 FY25, as against ₹ 126.99 crore in Q4 FY24. However, on a quarter-on-quarter (QoQ) basis, the figure declined by 17% from ₹ 172.71 crore posted in the third quarter of FY25. At the end of the March 2025 quarter, Harsh Goenka owned 26,915 shares or a 0.16% stake in the company and was classified as a promoter. The multibagger stock also recommended a solid dividend payout for its shareholders to the tune of ₹ 24 apiece. RPG Life Sciences Baord recommended a final dividend of ₹ 20 per equity share (250% on the face value of ₹ 8 each) and additionally a special dividend of ₹ 4 per equity share (50% on the face value of ₹ 8 each) on account of significant exceptional profit on assignment of land for the financial year 2024-25, subject to the approval of shareholders at the ensuing Annual General Meeting, the company said in an exchange filing on Monday. According to Trendlyne data, RPG Life Sciences has declared an equity dividend amounting to ₹ 16 per share in the past 12 months, resulting in a dividend yield of 0.72% based on the current market price. Following the earnings announcement, the multibagger small-cap stock jumped 12% to hit the day's high of ₹ 2366.60 apiece, as against its closing price of ₹ 2108.80. The company, which has a market capitalisation of ₹ 3,660 crore, has delivered solid returns to the investors, with the scrip up 41.24% in the last one year and 163% in the past two years. On longer time frames of five years and 10 years, RPG Life Sciences stock has rallied 766% and 1470%, respectively.
Business Standard
29-04-2025
- Business
- Business Standard
Indices drifts higher in early trade; Nifty above 24,400 level
The domestic equity indices traded with decent gains in early trade, despite mixed global cues and ongoing concerns over potential tariff changes and rising geopolitical tensions between India and Pakistan. The Nifty traded above the 24,400 level. PSU bank, media and oil & gas shares advanced, while pharma and FMCG shares declined. At 09:30 IST, the barometer index, the S&P BSE Sensex, surged 316.07 points or 0.39% to 80,547.10. The Nifty 50 index rose 90.30 points or 0.37% to 24,518.80. The broader market outperformed the frontline indices. The S&P BSE Mid-Cap index rose 0.79% and the S&P BSE Small-Cap index jumped 0.97%. The market breadth was strong. On the BSE, 2,152 shares rose and 479 shares fell. A total of 132 shares were unchanged. Foreign portfolio investors (FPIs) bought shares worth Rs 2,474.10 crore, while domestic institutional investors (DIIs) were net buyers to the tune of Rs 2,817.64 crore in the Indian equity market on 28 April 2025, provisional data showed. Stocks in Spotlight: RPG Life Sciences surged 8.84% after the company reported 64.3% jump in standalone net profit to Rs 117.35 crore in Q4 FY25 as compared with Rs 13.24 crore in Q4 FY24. Net sales increased 12.7% YoY to Rs 143.09 crore in Q4 FY25. The companys board recommends a final dividend of Rs 20 per share for FY25. UCO Bank rallied 4.35% after the banks standalone net profit jumped 24.1% to Rs 652.43 crore on 16.5% increase in total income to Rs 8136.79 crore in Q4 FY25 over Q4 FY24. Central Bank of India added 2.86% after the bank reported a 28% increase to Rs 1,033.55 crore on 7.6% rise in total income to Rs 10,432.56 crore in Q4 FY25 over Q4 FY24. Numbers to Track: The yield on India's 10-year benchmark federal paper was up 0.75% to 6.444 as compared with previous close 6.495. In the foreign exchange market, the rupee edged higher against the dollar. The partially convertible rupee was hovering at 85.1000, compared with its close of 85.2375 during the previous trading session. MCX Gold futures for 5 June 2025 settlement shed 0.85% to Rs 95,200. The US Dollar index (DXY), which tracks the greenback's value against a basket of currencies, was up 0.28% to 99.21. The United States 10-year bond yield rose 0.09% to 4.218. In the commodities market, Brent crude for May 2025 settlement shed 82 cents, or 0.54% to $65.32 a barrel. Global Markets: Asian stocks edged higher on Tuesday as investors waited to see the extent of the impact of U.S. President Donald Trump's tariffs on corporate earnings and economic data expected from Wall Street this week. Meanwhile, market watchers were glued to updates on negotiations between the U.S. and various countries in the region, hoping for any signs of a breakthrough. In Japan, markets were closed for a public holiday. Back in the U.S., Wall Street served up modest gains on Monday. The Dow Jones Industrial Average added 0.3%, the S&P 500 inched up 0.1%, and the Nasdaq Composite dipped ever so slightly by 0.1%, as investors digested fresh comments from U.S. Treasury Secretary Scott Bessent. In an interview, Bessent struck a cautiously optimistic tone, mentioning that many countries have offered "very good" tariff proposals to the U.S. He also emphasized that all parts of the U.S. government remain in touch with China although Beijing earlier insisted no talks had happened. Investors are gearing up for a packed calendar, featuring the Federal Reserves favorite inflation metric the PCE Price Index along with the highly anticipated monthly jobs report. Plus, first-quarter GDP numbers are due, which could set the tone for the markets heading into the summer. The so-called "Magnificent Seven" megacaps Apple, Microsoft, Amazon, and Meta Platforms among them are all set to drop their earnings this week.
